Ultragenyx Pharmaceutical

$128.53
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$4.39 (+3.54%) Today
$0.00 (0.00%) As of 11:00 PM UTC after-hours

Why Robinhood?

You can buy or sell RARE and other stocks, options, and ETFs commission-free!

About RARE

Ultragenyx Pharmaceutical Inc. Common Stock, also called Ultragenyx Pharmaceutical, is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA. The listed name for RARE is Ultragenyx Pharmaceutical Inc. Common Stock.

CEO
Emil D. Kakkis
Employees
740
Headquarters
Novato, California
Founded
2010
Market Cap
8.50B
Price-Earnings Ratio
Dividend Yield
Average Volume
332.59K
High Today
$129.91
Low Today
$124.17
Open Price
$124.54
Volume
408.59K
52 Week High
$129.91
52 Week Low
$31.99

Collections

RARE Earnings

-$2.05
-$1.37
-$0.68
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 11, After Hours

You May Also Like